Content contributed by the Alzheimers Association A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported recently at the Alzheimers Association International Conference (AAIC) 2024, in Philadelphia and online
Preclinical studies suggest that GLP-1 signaling in the central nervous system may influence neuronal activity patterns, though the clinical significance of these findings for human fatigue remains theoretical
weight loss -14 lbs Average member progress within the first 90 days of starting a consistent clinician-guided weight-loss program
Acetyl-L-carnitine and L-carnitine are absorbed into the bloodstream efficiently
We need muscle for longevity, to stay healthy, to help our metabolism, to ward off disease
The appropriate alternative depends on your individual clinical situation and treatment goals